Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).
US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.
Twist Bioscience has teamed up with Artisan Development Labs to discover new antibodies against five undisclosed targets.
Prellis Biologics and Bristol Myers Squibb have signed a multi-target collaboration and license agreement to discover antibodies.
Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced the extension of their oncology collaboration for first in human clinical trials for drug candidates LP-184 and LP-284.
Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.
Amgen has entered into a research collaboration agreement with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several modalities.
Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.
Under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.